
Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment
Keywords: Oral chemotherapy; Metronomic chemotherapy; Chk1 inhibitor; p53-deficient breast cancer; Doxorubicin; Synthetic lethality; MK-8776; Breast cancer;